Plasma Triglycerides and Cardiovascular Events in the Treating to New Targets and Incremental Decrease in End-Points Through Aggressive Lipid Lowering Trials of Statins in Patients With Coronary Artery Disease

Ole Faergeman, Ingar Holme, Rana Fayyad, Sonal Bhatia, Scott M Grundy, John J P Kastelein, John C. LaRosa, Mogens Lytken Larsen, Christina Lindahl, Anders G. Olsson, Matti J. Tikkanen, David D. Waters, Terje R. Pedersen

Research output: Contribution to journalArticle

106 Citations (Scopus)

Abstract

We determined the ability of in-trial measurements of triglycerides (TGs) to predict new cardiovascular events (CVEs) using data from the Incremental Decrease in End Points through Aggressive Lipid Lowering (IDEAL) and Treating to New Targets (TNT) trials. The trials compared atorvastatin 80 mg/day with moderate-dose statin therapy (simvastatin 20 to 40 mg/day in IDEAL and atorvastatin 10 mg/day in TNT) in patients with clinically evident coronary heart disease or a history of myocardial infarction. The outcome measurement in the present research was CVE occurring after the first year of the trial. After adjusting for age, gender, and study, risk of CVEs increased with increasing TGs (p <0.001 for trend across quintiles of TGs). Patients in the highest quintile had a 63% higher rate of CVEs than patients in the lowest quintile (hazard ratio 1.63, 95% confidence interval 1.46 to 1.81) and the relation of TGs to risk was apparent even within the normal range of TGs. The ability of TG measurements to predict risk decreased when high-density lipoprotein cholesterol and apolipoprotein B:apolipoprotein A-1 were included in the statistical analysis, and it was abolished with inclusion of further variables (diabetes, body mass index, glucose, hypertension, and smoking; (p = 0.044 and 0.621, respectively, for trend across quintiles of TGs). Similar results were obtained in patients in whom low-density lipoprotein cholesterol had been lowered to guideline-recommended levels. In conclusion, even slightly increased TG levels are associated with higher risk of recurrence of CVEs in statin-treated patients and should be considered a useful marker of risk.

Original languageEnglish (US)
Pages (from-to)459-463
Number of pages5
JournalAmerican Journal of Cardiology
Volume104
Issue number4
DOIs
StatePublished - Aug 15 2009

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Coronary Artery Disease
Triglycerides
Lipids
Aptitude
Simvastatin
Apolipoprotein A-I
Apolipoproteins B
LDL Cholesterol
HDL Cholesterol
Coronary Disease
Reference Values
Body Mass Index
Smoking
Myocardial Infarction
Guidelines
Confidence Intervals
Hypertension
Glucose
Recurrence

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Plasma Triglycerides and Cardiovascular Events in the Treating to New Targets and Incremental Decrease in End-Points Through Aggressive Lipid Lowering Trials of Statins in Patients With Coronary Artery Disease. / Faergeman, Ole; Holme, Ingar; Fayyad, Rana; Bhatia, Sonal; Grundy, Scott M; Kastelein, John J P; LaRosa, John C.; Larsen, Mogens Lytken; Lindahl, Christina; Olsson, Anders G.; Tikkanen, Matti J.; Waters, David D.; Pedersen, Terje R.

In: American Journal of Cardiology, Vol. 104, No. 4, 15.08.2009, p. 459-463.

Research output: Contribution to journalArticle

Faergeman, Ole ; Holme, Ingar ; Fayyad, Rana ; Bhatia, Sonal ; Grundy, Scott M ; Kastelein, John J P ; LaRosa, John C. ; Larsen, Mogens Lytken ; Lindahl, Christina ; Olsson, Anders G. ; Tikkanen, Matti J. ; Waters, David D. ; Pedersen, Terje R. / Plasma Triglycerides and Cardiovascular Events in the Treating to New Targets and Incremental Decrease in End-Points Through Aggressive Lipid Lowering Trials of Statins in Patients With Coronary Artery Disease. In: American Journal of Cardiology. 2009 ; Vol. 104, No. 4. pp. 459-463.
@article{7d0f96d2dcab4fa98b60335c1d749135,
title = "Plasma Triglycerides and Cardiovascular Events in the Treating to New Targets and Incremental Decrease in End-Points Through Aggressive Lipid Lowering Trials of Statins in Patients With Coronary Artery Disease",
abstract = "We determined the ability of in-trial measurements of triglycerides (TGs) to predict new cardiovascular events (CVEs) using data from the Incremental Decrease in End Points through Aggressive Lipid Lowering (IDEAL) and Treating to New Targets (TNT) trials. The trials compared atorvastatin 80 mg/day with moderate-dose statin therapy (simvastatin 20 to 40 mg/day in IDEAL and atorvastatin 10 mg/day in TNT) in patients with clinically evident coronary heart disease or a history of myocardial infarction. The outcome measurement in the present research was CVE occurring after the first year of the trial. After adjusting for age, gender, and study, risk of CVEs increased with increasing TGs (p <0.001 for trend across quintiles of TGs). Patients in the highest quintile had a 63{\%} higher rate of CVEs than patients in the lowest quintile (hazard ratio 1.63, 95{\%} confidence interval 1.46 to 1.81) and the relation of TGs to risk was apparent even within the normal range of TGs. The ability of TG measurements to predict risk decreased when high-density lipoprotein cholesterol and apolipoprotein B:apolipoprotein A-1 were included in the statistical analysis, and it was abolished with inclusion of further variables (diabetes, body mass index, glucose, hypertension, and smoking; (p = 0.044 and 0.621, respectively, for trend across quintiles of TGs). Similar results were obtained in patients in whom low-density lipoprotein cholesterol had been lowered to guideline-recommended levels. In conclusion, even slightly increased TG levels are associated with higher risk of recurrence of CVEs in statin-treated patients and should be considered a useful marker of risk.",
author = "Ole Faergeman and Ingar Holme and Rana Fayyad and Sonal Bhatia and Grundy, {Scott M} and Kastelein, {John J P} and LaRosa, {John C.} and Larsen, {Mogens Lytken} and Christina Lindahl and Olsson, {Anders G.} and Tikkanen, {Matti J.} and Waters, {David D.} and Pedersen, {Terje R.}",
year = "2009",
month = "8",
day = "15",
doi = "10.1016/j.amjcard.2009.04.008",
language = "English (US)",
volume = "104",
pages = "459--463",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Plasma Triglycerides and Cardiovascular Events in the Treating to New Targets and Incremental Decrease in End-Points Through Aggressive Lipid Lowering Trials of Statins in Patients With Coronary Artery Disease

AU - Faergeman, Ole

AU - Holme, Ingar

AU - Fayyad, Rana

AU - Bhatia, Sonal

AU - Grundy, Scott M

AU - Kastelein, John J P

AU - LaRosa, John C.

AU - Larsen, Mogens Lytken

AU - Lindahl, Christina

AU - Olsson, Anders G.

AU - Tikkanen, Matti J.

AU - Waters, David D.

AU - Pedersen, Terje R.

PY - 2009/8/15

Y1 - 2009/8/15

N2 - We determined the ability of in-trial measurements of triglycerides (TGs) to predict new cardiovascular events (CVEs) using data from the Incremental Decrease in End Points through Aggressive Lipid Lowering (IDEAL) and Treating to New Targets (TNT) trials. The trials compared atorvastatin 80 mg/day with moderate-dose statin therapy (simvastatin 20 to 40 mg/day in IDEAL and atorvastatin 10 mg/day in TNT) in patients with clinically evident coronary heart disease or a history of myocardial infarction. The outcome measurement in the present research was CVE occurring after the first year of the trial. After adjusting for age, gender, and study, risk of CVEs increased with increasing TGs (p <0.001 for trend across quintiles of TGs). Patients in the highest quintile had a 63% higher rate of CVEs than patients in the lowest quintile (hazard ratio 1.63, 95% confidence interval 1.46 to 1.81) and the relation of TGs to risk was apparent even within the normal range of TGs. The ability of TG measurements to predict risk decreased when high-density lipoprotein cholesterol and apolipoprotein B:apolipoprotein A-1 were included in the statistical analysis, and it was abolished with inclusion of further variables (diabetes, body mass index, glucose, hypertension, and smoking; (p = 0.044 and 0.621, respectively, for trend across quintiles of TGs). Similar results were obtained in patients in whom low-density lipoprotein cholesterol had been lowered to guideline-recommended levels. In conclusion, even slightly increased TG levels are associated with higher risk of recurrence of CVEs in statin-treated patients and should be considered a useful marker of risk.

AB - We determined the ability of in-trial measurements of triglycerides (TGs) to predict new cardiovascular events (CVEs) using data from the Incremental Decrease in End Points through Aggressive Lipid Lowering (IDEAL) and Treating to New Targets (TNT) trials. The trials compared atorvastatin 80 mg/day with moderate-dose statin therapy (simvastatin 20 to 40 mg/day in IDEAL and atorvastatin 10 mg/day in TNT) in patients with clinically evident coronary heart disease or a history of myocardial infarction. The outcome measurement in the present research was CVE occurring after the first year of the trial. After adjusting for age, gender, and study, risk of CVEs increased with increasing TGs (p <0.001 for trend across quintiles of TGs). Patients in the highest quintile had a 63% higher rate of CVEs than patients in the lowest quintile (hazard ratio 1.63, 95% confidence interval 1.46 to 1.81) and the relation of TGs to risk was apparent even within the normal range of TGs. The ability of TG measurements to predict risk decreased when high-density lipoprotein cholesterol and apolipoprotein B:apolipoprotein A-1 were included in the statistical analysis, and it was abolished with inclusion of further variables (diabetes, body mass index, glucose, hypertension, and smoking; (p = 0.044 and 0.621, respectively, for trend across quintiles of TGs). Similar results were obtained in patients in whom low-density lipoprotein cholesterol had been lowered to guideline-recommended levels. In conclusion, even slightly increased TG levels are associated with higher risk of recurrence of CVEs in statin-treated patients and should be considered a useful marker of risk.

UR - http://www.scopus.com/inward/record.url?scp=68049114763&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68049114763&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2009.04.008

DO - 10.1016/j.amjcard.2009.04.008

M3 - Article

C2 - 19660594

AN - SCOPUS:68049114763

VL - 104

SP - 459

EP - 463

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 4

ER -